Cipher Pharmaceuticals Inc. (TSX:CPH)

Market Cap	315.56M
Revenue (ttm)	48.00M
Net Income (ttm)	16.61M
Shares Out	25.61M
EPS (ttm)	0.66
PE Ratio	18.61
Forward PE	13.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,036
Average Volume	33,700
Open	12.87
Previous Close	12.65
Day's Range	12.30 - 12.87
52-Week Range	7.90 - 19.69
Beta	1.14
RSI	48.77
Earnings Date	Mar 14, 2025

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwante...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CPH

Financial Performance

In 2024, Cipher Pharmaceuticals's revenue was $33.36 million, an increase of 57.66% compared to the previous year's $21.16 million. Earnings were $11.55 million, a decrease of -43.36%.

Financial numbers in USD